GLIBINE imatinib 400 mg film-coated tablets blister pack

国家: 澳大利亚

语言: 英文

来源: Department of Health (Therapeutic Goods Administration)

现在购买

公众评估报告 公众评估报告 (PAR)
08-11-2017

有效成分:

imatinib mesilate, Quantity: 477.877 mg (Equivalent: imatinib, Qty 400 mg)

可用日期:

Teva Pharma Australia Pty Ltd

INN(国际名称):

imatinib mesilate

药物剂型:

Tablet, film coated

组成:

Excipient Ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol

给药途径:

Oral

每包单位数:

30 film-coated tablets, 90 film-coated tablets

处方类型:

(S4) Prescription Only Medicine

疗效迹象:

1) GLIBINE (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (CML). 2) GLIBINE (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. 3) GLIBINE (imatinib) is indicated for the treatment of adult patients with relapsed or refractory Ph+ALL as monotherapy. 4) GLIBINE (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements, where conventional therapies have failed. 5) GLIBINE (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), where conventional therapies have failed. 6) GLIBINE (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL). 7) GLIBINE (imatinib) is indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) 8) GLIBINE (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of KIT (CD117)-positive primary GIST. 9) GLIBINE (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).

產品總結:

Visual Identification: Imatinib tablets 400 mg are dark yellow to brownish oblong film coated tablets debossed with IT and 4 divided by score line on one side.; Container Type: Blister Pack; Container Material: PVC/PE/PVDC/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

授权状态:

Licence status A

授权日期:

2016-06-10